FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 820 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Coronavirus and cancer – July updates July 7, 2020 ctDNA-Guided Treatment Influence on Survival in Advanced NSCLC November 21, 2022 People who’ve had radiotherapy shape our new policy calls May 4, 2023 Repurposing radiotherapy drugs could give immunotherapy a boost November 11, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab ESMO Gynaecological Cancers Congress 2022, 17 – 18 June 2022 Valencia,... EMA Recommends Granting a Marketing Authorisation for Equidacent ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany
